✦ LIBER ✦

Involvement of the B-lymphoid system in chronic myelogenous leukaemia

✍ Scribed by Martin, Paul J.; Najfeld, Vesna; Hansen, John A.; Penfold, Grace K.; Jacobson, Robert J.; Fialkow, Philip J.

Book ID: 109719573
Publisher: Nature Publishing Group
Year: 1980
Tongue: English
Weight: 256 KB
Volume: 287
Category: Article
ISSN: 0028-0836
DOI: 10.1038/287049a0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

ABL amplification in a patient with lymp

ABL amplification in a patient with lymphoid blast crisis of chronic myelogenous leukaemia

✍ L. Kenner; C. Beham-Schmid; R. Kerbl; H. H. Schmidt; H. Sill; G. Hoefler 📂 Article 📅 1999 🏛 Springer 🌐 English ⚖ 381 KB

Central nervous system involvement at pr

Central nervous system involvement at presentation in the chronic phase of chronic myelogenous leukemia in childhood

✍ Richard J. Meyer; Janet Cuttner 📂 Article 📅 1978 🏛 John Wiley and Sons 🌐 English ⚖ 717 KB

Mechanisms of BCR–ABL in the pathogenesi

Mechanisms of BCR–ABL in the pathogenesis of chronic myelogenous leukaemia

✍ Ren, Ruibao 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 291 KB

Return of Leucocytes to the Bone Marrow

Return of Leucocytes to the Bone Marrow in Chronic Myelogenous Leukaemia

✍ MOXLEY, JOHN H.; PERRY, SEYMOUR; WEISS, GEORGE H.; ZELEN, MARVIN 📂 Article 📅 1965 🏛 Nature Publishing Group 🌐 English ⚖ 200 KB

Clinical and cytogenetic findings in the

Clinical and cytogenetic findings in the terminal phase of chronic myelogenous leukaemia

✍ E. Castro-Sierra; L. Z. Gorman; H. Merker; P. Obrecht; U. Wolf 📂 Article 📅 1967 🏛 Springer 🌐 English ⚖ 634 KB

Oral idarubicin in the treatment of acut

Oral idarubicin in the treatment of acute myelogenous leukaemia and the blast phase of chronic myeloid leukaemia

✍ S. T. A. Malik; J. Tucker; A. Z. S. Rohatiner; W. Brace; T. A. Lister 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 307 KB

Fourteen patients with poor-risk acute myelogenous leukaemia (AML) and five patients with accelerated phase/blast crisis chronic myeloid leukaemia (CML) were treated with 3 days of oral idarubicin (25 mg/m2/ day). No complete remissions or return to chronic phase CML were observed. A fall in the per